Cargando…
Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial
Background: Shigella spp. and enterotoxigenic Escherichia coli (ETEC) cause high morbidity and mortality worldwide, yet no licensed vaccines are available to prevent corresponding infections. A live attenuated non-invasive Shigella vaccine strain lacking LPS O-antigen and expressing the ETEC toxoids...
Autores principales: | Girardi, Petra, Harutyunyan, Shushan, Neuhauser, Irene, Glaninger, Katharina, Korda, Orsolya, Nagy, Gábor, Nagy, Eszter, Szijártó, Valéria, Pall, Denes, Szarka, Krisztina, Kardos, Gábor, Henics, Tamás, Malinoski, Frank J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879453/ https://www.ncbi.nlm.nih.gov/pubmed/35214798 http://dx.doi.org/10.3390/vaccines10020340 |
Ejemplares similares
-
Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC
por: Harutyunyan, Shushan, et al.
Publicado: (2020) -
Anti-Toxin Responses to Natural Enterotoxigenic Escherichia coli (ETEC) Infection in Adults and Children in Bangladesh
por: Girardi, Petra, et al.
Publicado: (2023) -
Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus
por: Das, Jai K, et al.
Publicado: (2013) -
Immunogenic evaluation of chimeric recombinant protein against ETEC, EHEC and Shigella
por: Khalouie, Farzane, et al.
Publicado: (2017) -
Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy
por: Hosangadi, Divya, et al.
Publicado: (2019)